467 related articles for article (PubMed ID: 30354249)
1. Microfluidic Modeling of Thrombolysis.
Loyau S; Ho-Tin-Noé B; Bourrienne MC; Boulaftali Y; Jandrot-Perrus M
Arterioscler Thromb Vasc Biol; 2018 Nov; 38(11):2626-2637. PubMed ID: 30354249
[TBL] [Abstract][Full Text] [Related]
2. Real-time measurement of lysis of mural platelet deposits by fibrinolytic agents under arterial flow.
Graham DA; Huang TC; Keyt BA; Alevriadou BR
Ann Biomed Eng; 1998; 26(4):712-24. PubMed ID: 9662163
[TBL] [Abstract][Full Text] [Related]
3. Differential effects of c7E3 Fab on thrombus formation and rt-PA-Mediated thrombolysis under flow conditions.
Huang TC; Jordan RE; Hantgan RR; Alevriadou BR
Thromb Res; 2001 Jun; 102(5):411-25. PubMed ID: 11395127
[TBL] [Abstract][Full Text] [Related]
4. Plasminogen associates with phosphatidylserine-exposing platelets and contributes to thrombus lysis under flow.
Whyte CS; Swieringa F; Mastenbroek TG; Lionikiene AS; Lancé MD; van der Meijden PE; Heemskerk JW; Mutch NJ
Blood; 2015 Apr; 125(16):2568-78. PubMed ID: 25712989
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological Blockade of Glycoprotein VI Promotes Thrombus Disaggregation in the Absence of Thrombin.
Ahmed MU; Kaneva V; Loyau S; Nechipurenko D; Receveur N; Le Bris M; Janus-Bell E; Didelot M; Rauch A; Susen S; Chakfé N; Lanza F; Gardiner EE; Andrews RK; Panteleev M; Gachet C; Jandrot-Perrus M; Mangin PH
Arterioscler Thromb Vasc Biol; 2020 Sep; 40(9):2127-2142. PubMed ID: 32698684
[TBL] [Abstract][Full Text] [Related]
6. The mouse dorsal skinfold chamber as a model for the study of thrombolysis by intravital microscopy.
Boulaftali Y; Lamrani L; Rouzaud MC; Loyau S; Jandrot-Perrus M; Bouton MC; Ho-Tin-Noé B
Thromb Haemost; 2012 May; 107(5):962-71. PubMed ID: 22552380
[TBL] [Abstract][Full Text] [Related]
7. Plasminogen activator inhibitor-1 released from activated platelets plays a key role in thrombolysis resistance. Studies with thrombi generated in the Chandler loop.
Stringer HA; van Swieten P; Heijnen HF; Sixma JJ; Pannekoek H
Arterioscler Thromb; 1994 Sep; 14(9):1452-8. PubMed ID: 8068607
[TBL] [Abstract][Full Text] [Related]
8. Uncoupling fibrin from integrin receptors hastens fibrinolysis at the platelet-fibrin interface.
Braaten JV; Jerome WG; Hantgan RR
Blood; 1994 Feb; 83(4):982-93. PubMed ID: 8111066
[TBL] [Abstract][Full Text] [Related]
9. Thrombus-targeted nanocarrier attenuates bleeding complications associated with conventional thrombolytic therapy.
Absar S; Nahar K; Kwon YM; Ahsan F
Pharm Res; 2013 Jun; 30(6):1663-76. PubMed ID: 23468049
[TBL] [Abstract][Full Text] [Related]
10. Thrombus lysis by uPA, scuPA and tPA is regulated by plasma TAFI.
Mutch NJ; Moore NR; Wang E; Booth NA
J Thromb Haemost; 2003 Sep; 1(9):2000-7. PubMed ID: 12941043
[TBL] [Abstract][Full Text] [Related]
11. Absence of paradoxical thrombin activation by fibrin-specific thrombolytics in acute myocardial infarction: comparison of single-bolus tenecteplase and front-loaded alteplase.
Szabo S; Letsch R; Ehlers R; Walter T; Kazmaier S; Helber U; Hoffmeister HM
Thromb Res; 2002 Apr; 106(2):113-9. PubMed ID: 12182909
[TBL] [Abstract][Full Text] [Related]
12. Thrombolytic and haemorrhagic effects of bolus doses of tissue-type plasminogen activator and a hybrid plasminogen activator with prolonged plasma half-life (K2tu-PA: CGP 42935).
Agnelli G; Pascucci C; Nenci GG; Mele A; Bürgi R; Heim J
Thromb Haemost; 1993 Aug; 70(2):294-300. PubMed ID: 8236138
[TBL] [Abstract][Full Text] [Related]
13. Rapid dissociation of platelet-rich fibrin clots in vitro by a combination of plasminogen activators and antiplatelet agents.
Lam SC; Dieter JP; Strebel LC; Taylor TM; Muscolino G; Feinberg H; Le Breton GC
J Pharmacol Exp Ther; 1991 Dec; 259(3):1371-8. PubMed ID: 1762085
[TBL] [Abstract][Full Text] [Related]
14. Fibrin Modulates Shear-Induced NETosis in Sterile Occlusive Thrombi Formed under Haemodynamic Flow.
Yu X; Diamond SL
Thromb Haemost; 2019 Apr; 119(4):586-593. PubMed ID: 30722079
[TBL] [Abstract][Full Text] [Related]
15. Releasing the Brakes on the Fibrinolytic System in Pulmonary Emboli: Unique Effects of Plasminogen Activation and α2-Antiplasmin Inactivation.
Singh S; Houng A; Reed GL
Circulation; 2017 Mar; 135(11):1011-1020. PubMed ID: 28028005
[TBL] [Abstract][Full Text] [Related]
16. Reduction in stent and vascular graft thrombosis and enhancement of thrombolysis by recombinant Lys-plasminogen in nonhuman primates.
Sundell IB; Marzec UM; Kelly AB; Chronos NA; Petersen LC; Hanson SR; Hedner U; Harker LA
Circulation; 1997 Aug; 96(3):941-8. PubMed ID: 9264505
[TBL] [Abstract][Full Text] [Related]
17. A Fibrinogen-Mimicking, Activated-Platelet-Sensitive Nanocoacervate Enhances Thrombus Targeting and Penetration of Tissue Plasminogen Activator for Effective Thrombolytic Therapy.
Huang Y; Jiang J; Ren J; Guo Y; Zhao Q; Zhou J; Li Y; Chen R
Adv Healthc Mater; 2022 Oct; 11(19):e2201265. PubMed ID: 35864062
[TBL] [Abstract][Full Text] [Related]
18. Fibrinolytic profiles in local low-dose thrombolysis with streptokinase and recombinant tissue plasminogen activator.
Berridge DC; Earnshaw JJ; Westby JC; Makin GS; Hopkinson BR
Thromb Haemost; 1989 Apr; 61(2):275-8. PubMed ID: 2501898
[TBL] [Abstract][Full Text] [Related]
19. Thrombus growth and embolism on tissue factor-bearing collagen surfaces under flow: role of thrombin with and without fibrin.
Colace TV; Muthard RW; Diamond SL
Arterioscler Thromb Vasc Biol; 2012 Jun; 32(6):1466-76. PubMed ID: 22516070
[TBL] [Abstract][Full Text] [Related]
20. An experimental and theoretical study on the dissolution of mural fibrin clots by tissue-type plasminogen activator.
Wootton DM; Popel AS; Alevriadou BR
Biotechnol Bioeng; 2002 Feb; 77(4):405-19. PubMed ID: 11787013
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
